MedPath

A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values

Not Applicable
Completed
Conditions
Prostate Cancer
Registration Number
NCT01553838
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Brief Summary

The purpose of this study is to determine whether MRI guided prostate biopsy achieves higher prostate cancer detection rates compared with transrectal ultrasound guided prostate biopsy in patients with increased PSA values \> 4.0 ng/ml.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
185
Inclusion Criteria
  • PSA > 4.0 ng/ml
  • written informed consent
  • age >18
Exclusion Criteria
  • patients with prostate cancer
  • patients with prior prostate biopsy
  • patients with contraindications against MRI or biopsy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Prostate cancer detection rate3 years
Secondary Outcome Measures
NameTimeMethod
Number of Participants with Adverse Events as a measure of Safety and Tolerability3 years

Trial Locations

Locations (1)

Department of Urology

🇩🇪

Duesseldorf, Germany

Department of Urology
🇩🇪Duesseldorf, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.